JP2017515806A5 - - Google Patents

Download PDF

Info

Publication number
JP2017515806A5
JP2017515806A5 JP2016561850A JP2016561850A JP2017515806A5 JP 2017515806 A5 JP2017515806 A5 JP 2017515806A5 JP 2016561850 A JP2016561850 A JP 2016561850A JP 2016561850 A JP2016561850 A JP 2016561850A JP 2017515806 A5 JP2017515806 A5 JP 2017515806A5
Authority
JP
Japan
Prior art keywords
composition
cancer
poxvirus
composition according
oxaliplatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016561850A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017515806A (ja
JP6657115B2 (ja
Filing date
Publication date
Priority claimed from US14/249,713 external-priority patent/US9687515B2/en
Application filed filed Critical
Priority claimed from PCT/EP2015/057654 external-priority patent/WO2015155263A1/en
Publication of JP2017515806A publication Critical patent/JP2017515806A/ja
Publication of JP2017515806A5 publication Critical patent/JP2017515806A5/ja
Application granted granted Critical
Publication of JP6657115B2 publication Critical patent/JP6657115B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016561850A 2014-04-10 2015-04-09 ポックスウイルス腫瘍細胞崩壊性ベクター Active JP6657115B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/249,713 US9687515B2 (en) 2007-11-19 2014-04-10 Poxviral oncolytic vectors
US14/249,713 2014-04-10
PCT/EP2015/057654 WO2015155263A1 (en) 2014-04-10 2015-04-09 Poxviral oncolytic vectors

Publications (3)

Publication Number Publication Date
JP2017515806A JP2017515806A (ja) 2017-06-15
JP2017515806A5 true JP2017515806A5 (2) 2018-04-19
JP6657115B2 JP6657115B2 (ja) 2020-03-04

Family

ID=53051793

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016561850A Active JP6657115B2 (ja) 2014-04-10 2015-04-09 ポックスウイルス腫瘍細胞崩壊性ベクター

Country Status (10)

Country Link
EP (1) EP3129037B1 (2)
JP (1) JP6657115B2 (2)
KR (1) KR102457060B1 (2)
CN (1) CN106413726B (2)
AU (1) AU2015243297B2 (2)
CA (1) CA2943871C (2)
DK (1) DK3129037T3 (2)
ES (1) ES2768715T3 (2)
IL (1) IL247535B (2)
WO (1) WO2015155263A1 (2)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018091680A1 (en) * 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
EP3610870A4 (en) * 2017-03-31 2020-12-09 Ogata, Hisanobu METHOD OF EXPANSION OF AN ONCOLYTIC VIRUS AND ANTI-TUMOR AGENT
US20220056481A1 (en) * 2018-12-28 2022-02-24 Transgene M2-defective poxvirus
CN110747174A (zh) * 2019-10-30 2020-02-04 青岛宁逸生物科技有限公司 一种用于肿瘤治疗的重组病毒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
DE69233158T2 (de) * 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5856153A (en) 1994-11-17 1999-01-05 Cayla Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases
FR2777570A1 (fr) 1998-04-17 1999-10-22 Transgene Sa Mutant ayant une activite phosphoribosyl transferase
WO2000073479A1 (en) * 1999-05-28 2000-12-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
KR20120002613A (ko) 2002-08-12 2012-01-06 제네렉스, 인코포레이티드 폭스바이러스 및 암과 관련된 방법 및 조성물
JP4672659B2 (ja) 2003-07-21 2011-04-20 トランジェーヌ、ソシエテ、アノニム 改善されたシトシンデアミナーゼ活性を有するポリペプチド
AU2005300248B2 (en) 2004-11-08 2012-04-26 Transgene S.A. Kit of parts designed for implementing an antitumoral or antiviral treatment in a mammal
KR20080084528A (ko) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
JP2010533718A (ja) * 2007-07-18 2010-10-28 ジェネラックス・コーポレイション 腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用
RU2503717C2 (ru) * 2007-11-19 2014-01-10 Трансжене Са Поксвирусные онколитические векторы
US20100173013A1 (en) * 2009-01-08 2010-07-08 Denis Drygin Treatment of neoplastic disorders using combination therapies
CA2709292A1 (en) * 2009-07-10 2011-01-10 The Governors Of The University Of Alberta Oncolytic viruses and methods for treating neoplastic disorders

Similar Documents

Publication Publication Date Title
DK2212423T3 (en) oncolytic poxvirus vectors
JP2013189456A5 (2)
CA3031416C (en) Recombinant vaccinia virus and use thereof
JP2012067116A5 (2)
ES2905478T3 (es) Virus oncolíticos y moléculas terapéuticas
KR20170084034A (ko) 암 치료용 의약 조성물 제조에서의 아젤니디핀의 용도
JP2017523777A5 (2)
WO2017037292A1 (en) Combination of a dhodh inhibitor and a her inhibitor for use in the treatment of cancer
JP2016506413A5 (2)
ES2946472T3 (es) Agente antitumoral y potenciador del efecto antitumoral
EP3293201B1 (en) Combining adenovirus and checkpoint inhibitors for treating cancer
JP2013516454A5 (2)
JP2017515806A5 (2)
JP2016224056A5 (2)
WO2016210376A3 (en) Therapeutic peptides and methods of use thereof
JP2019038796A5 (2)
US20240002547A1 (en) Therapeutic multi-targeting constructs and uses thereof
Parrasia et al. Targeting pancreatic ductal adenocarcinoma (PDAC)
JP2019038797A5 (2)
IL272874B1 (en) [6r]-mthf an efficient folate alternative in 5-fluorouracil based chemotherapy
JP2018100243A5 (2)
Shih et al. Bozitinib, a highly selective inhibitor of cMet, demonstrates robust activity in gastric, lung, hepatic and pancreatic in vivo models
JP2021511344A5 (2)
CA2943871C (en) POXVIRAL ONCOLYTIC VECTORS
WO2020011754A1 (en) Chimeric vaccinia viruses